ba 41899 has been researched along with Cardiac Failure in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fuhrer, W; Herold, P; Herzig, JW; Leutert, T; Meier, M; Rihs, G; Schenker, K; Stutz, S; Wenk, P; Zbinden, P | 1 |
Endoh, M | 1 |
1 review(s) available for ba 41899 and Cardiac Failure
Article | Year |
---|---|
Cardiac Ca2+ signaling and Ca2+ sensitizers.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Angiotensin II; Animals; Azocines; Calcium; Calcium Signaling; Cardiotonic Agents; Cholinergic Agonists; Dihydropyridines; Endothelins; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocardium; Phosphodiesterase Inhibitors; Pyridazines; Quinolines; Simendan; Thiadiazines; Troponin C | 2008 |
1 other study(ies) available for ba 41899 and Cardiac Failure
Article | Year |
---|---|
5-Methyl-6-phenyl-1,3,5,6-tetrahydro-3,6-methano-1,5-benzodiazocine-2,4-dione (BA 41899): representative of a novel class of purely calcium-sensitizing agents.
Topics: Animals; Azocines; Calcium; Cardiotonic Agents; Electric Stimulation; Guinea Pigs; Heart Atria; Heart Failure; Imidazoles; In Vitro Techniques; Isometric Contraction; Myocardial Contraction; Myocardium; Phosphodiesterase Inhibitors; Sensitivity and Specificity; Stereoisomerism; Swine | 1995 |